The rare disease community is witnessing a transformative period in therapeutic development, with Mucopolysaccharidosis Type I (MPS I) at the forefront of groundbreaking medical advances. This inherited metabolic disorder, characterized by the accumulation of glycosaminoglycans due to alpha-L-iduronidase deficiency, has historically presented limited treatment options for affected families. However, the current therapeutic landscape is rapidly… Read.